Percutaneous Embolectomy, Ultrasound Assisted Thrombolysis or Heparin for Intermediate High Risk Pulmonary Embolism

Pulmonary Embolism Clinical Trial

— STRATIFY-II  

Official title:

Percutaneous Embolectomy, Ultrasund Assisted Low Dose Thrombolysis or Heparin for Intermediate High Risk Pulmonary Embolism

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT06453876
• Other study ID #: STRATIFY-II 1.0 (04OCT2023)
• Status: Active, not recruiting
• Phase: Phase 3
• Start date: June 6, 2019
• Est. completion date: October 31, 2024

Study information

• Verified date: June 2024
• Source: Rigshospitalet, Denmark
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The STRATIFY II trial investigates the efficacy of three different approaches to reducing thrombus burdon in patients with acute intermediate high-risk pulmonary embolism: percutaneous embolectomy (the Flow Triever® system, INARI medical), USAT (EKOS® system, Boston Scientific with low dose alteplase) and heparin with the option to perform full-dose thrombolysis. As a co-primary secondary end point the trial assess the incremental efficacy of the embolectomy vs the catheter based low dose thrombolysis approach.

Thus the two main hypothesis being tested are:

1. Thrombus burden reduction after 48-96 h is increased with a catheter based (embolectomy or USAT) compared to the a heparin with optional high dose thrombolysis approach (1st co-primary outcome)

2. Thrombus burden reduction after 48-96 h is increased with percutaneous embolectomy compared to USAT with low-dose alteplase (2nd co-primary outcome)

Description:

BACKGROUND Intermediate high-risk PE is associated with an up to 10% risk of death even if the circulations of the patient is only marginally impacted (1). Full dose thrombolysis has been investigated is two randomized trials but finding the intervention to be efficacious in preventing hemodynamic deterioration, but at the cost of an increased risk og bleeding with cancels the benefit of thrombolysis with regards to risk of death (2, 3). Therefore recent guidelines suggest that patients are managed by heparins with thrombolysis available as a rescue therapy if the patient deteriorates hemodynamically (1). Further two small clinical have trials have investigated the role of low dose thrombolysis finding a substantial reduction in late incidence of pulmonary hypertension (4) and similar efficacy of half dose thrombolysis and lower occurrence of bleeding compared to full doses thrombolysis (5).

Since then catheter based interventions for administering low Thrombolysis for acute PE has been introduced. Some interventionalists use simple catheters while the EKOS® system of USAT claims to increase the efficacy of thrombolytics by applying a mechanical force from ultrasound emitting crystals nead the emboli while slowly administering the thrombolytics near the thrombus in the pulmonary arteries. The USAT techniques has been tested in a small randomized trial, finding the treatment to efficacious in terms of reducing right heart dilatation (6). Later a dose finding RCT should similar efficacy of dosages of alteplase in USAT ranging from 4 mg to 24 mg per catheter (7). The HI-PEITHO trial (NCT04790370) is a 406 patient trial current enrolling patients, and the STRATIFY trial from our group (NCT04088292) is a 210 patient trial also currently including patients, and thus more knowledge of the efficacy of this approach will be available in 1-2 years.

Recently catheter-based embolectomy has been introduced. While no randomized trials have compared this technique to the guidelines supported strategy of UFH or LMWH, several registries and sace series have been put forward, suggesting a significant efficacy and a acceptable risk of bleeding. The INARI FlowTriever system ® has been use in a substantial number of patients, but have only been reported in none peer-reviewed presentation as results of two registries comparing patients treated with percutaneous embolectomy and a registry describing 'real world data' has been presented online (8) and in comment section in medical journals (9). An ongoing randomized trial comparing percutaneous embolectomy and catheter directed thrombolysis, is currently recruiting patients (NCT05111613)(10) and another comparing embolectomy and heparins is planned (NCT06055920).

Balancing the risk and efficacy of the treatment strategy remains important and since a lack of data both proving the efficacy of the novel treatment alternatives and limited data comparing efficacy in trial with a suitable design, a clinical equipoise remains.

TRIAL OBJECTIVES AND HYPOTHESIS The STRATIFY II trial investigates the efficacy of three different approaches to reducing thrombus burdon in patients with acute intermediate high-risk pulmonary embolism: percutaneous embolectomy (the Flow Triever® system, INARI medical), USAT (EKOS® system, Boston Scientific with low dose alteplase) and heparin with the option to perform full-dose thrombolysis. As a co-primary secondary end point the trial assess the incremental efficacy of the embolectomy vs the catheter based low dose thrombolysis approach.

Thus the two main hypothesis being tested are:

1. Thrombus burden reduction after 48-96 h is increased with a catheter based (embolectomy or USAT) compared to the a heparin with optional high dose thrombolysis approach (1st co-primary outcome)

2. Thrombus burden reduction after 48-96 h is increased with percutaneous embolectomy compared to USAT with low-dose alteplase (2nd co-primary outcome) SETTING AND PATIENT POPULATION SETTING The trial is including patients diagnosed with an acute PE (defined as symptom duration of less than 14 days) with intermediate- high risk , please see section of definition below. Patients are recruited from participating centers by the attending cardiologist, either in the emergency room or at the ward. Since risk stratification most often involves a cardiologist the investigators expect the majority of patients to be included in the trial immediately after risk stratification.

The participants will be informed on the possible inclusion in the trial in the ward, and every measure possible will be taken to ensure a quit environment for the information. The patient will be informed about their right to have an assessor present during the information session, and that they may take the time needed to consider their participation in the trial and giving their informed consent. The informed consent will be obtained soon after the patient have been informed on their diagnosis of intermediate-high risk PE.

DEFINITIONS Definition of Intermedidate- high risk PE is based on ESC guideline classification from 2019 (1) as identification of PE in the pulmonary main trunk, main and segmental pulmonary arteries on CT angiography performed as part of the diagnostic work-up of patients with clinical suspicion of acute PE RV dysfunction is defined as

• RV/LV ratio of > 1 on CT angiography or echocardiography (apical 4 chamber view in-diastole) OR

• RV systolic function by visual assessment or TAPSE < 18 mm OR

• TR gradient > 40 mmHg Elevated Cardiac Biomarker

• Increase in cardiac Troponins (I or T) above normal OR

• Increase Creatine Kinase MB (CKMB) above normal OR

• Increase in NT-pro-BNP above normal In the absence of shock at time of screening defined as

• Systolic blood pressure > 100 mmHg INCLUSION CRITERIA

1. Age ≥ 18 years

2. Informed consent for trial participation

3. Intermediate high-risk PE according to ESC criteria

4. Thrombus visible in main, lobar or segmental pulmonary arteries on CT angiography

5. 14 days of symptoms or less EXCLUSION CRITERIA

1. Altered mental state (GCS < 14)

2. No qualifying CT angiography performed (> 24 hour since CT angiography)

3. Females of child bearing potential, unless negative HCG test is present

4. Thrombolysis for PE within 14 days of randomization

5. Thrombus passing through patent Foramen Ovale (risk of paradoxical embolism)

6. Ongoing oral anticoagulation therapy (heparins, aspirin, antiplatelet therapy and NOAC allowed)

7. Comorbidity making 6 months survival unlikely

8. Absolute contraindications for thrombolysis

1. Hemorrhagic stroke or stroke of unknown origin at any time

2. Ischemic stroke in the preceding 6 months

3. Central nervous system damage or neoplasms

4. Recent major trauma/surgery/head injury in the preceding 3 weeks

5. Gastrointestinal bleeding within the last month

6. Known bleeding risk Relative contraindications do not preclude randomization. Relative contraindications include: Transient ischemic attack in the preceding 6 months, Oral anticoagulant therapy, Pregnancy, or within one week post partum, Non-compressible puncture site, Traumatic resuscitation, Refractory hypertension (systolic blood pressure >180 mm Hg), Advanced liver disease, Infective endocarditis, Active peptic ulcer OUTCOMES CO-PRIMARY ENDPOINT

• Reduction in modified Miller score (score of thrombus involvement and segmental flow)(11, 12) comparing percutaneous treated groups (embolectomy and USAT combined) to heparin/LMWH group, p<0.01 (n=140 vs. n=70).

• Reduction in modified Miller score (score of thrombus involvement and segmental flow)(11, 12) comparing percutaneous embolectomy and USAT, p<0.04 (n=70 vs n=70) SECONDARY ENDPOINTS

• • Bleeding complications (major and minor bleeding complication according to the Thrombolysis in Myocardial Infarction classification)

• Duration of index admission, including hospital-based rehabilitation

• Dyspnoea index (Visual analogue scale) after 48-96 h and after 3 months

• FiO2, blood pressure, and respiratory rate, heart rate at time of follow-up CTPA

• Mortality in the three groups (log-rank), and hazard ratio in multivariable analysis using the UFH/LMWH as a reference

• Incidence of TR gradient > 40 mmHg at 3 months follow-up echocardiography

• 6MWT at 3 months follow up comparing the three groups

• Quality of life at 3 months follow-up comparing the three groups (PEmb-Qol and 5Q-5D-5L)

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 210
• Est. completion date: October 31, 2024
• Est. primary completion date: June 5, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Age = 18 years

2. Informed consent for trial participation

3. Intermediate high-risk PE according to ESC criteria

4. Thrombus visible in main, lobar or segmental pulmonary arteries on CT angiography

5. 14 days of symptoms or less

Exclusion Criteria:

1. Altered mental state (GCS < 14)

2. No qualifying CT angiography performed (> 24 hour since CT angiography)

3. Females of child bearing potential, unless negative HCG test is present

4. Thrombolysis for PE within 14 days of randomization

5. Thrombus passing through patent Foramen Ovale (risk of paradoxical embolism)

6. Ongoing oral anticoagulation therapy (heparins, aspirin, antiplatelet therapy and NOAC allowed)

7. Comorbidity making 6 months survival unlikely

8. Absolute contraindications for thrombolysis

1. Hemorrhagic stroke or stroke of unknown origin at any time

2. Ischemic stroke in the preceding 6 months

3. Central nervous system damage or neoplasms

4. Recent major trauma/surgery/head injury in the preceding 3 weeks

5. Gastrointestinal bleeding within the last month

6. Known bleeding risk Relative contraindications do not preclude randomization. Relative contraindications include: Transient ischemic attack in the preceding 6 months, Oral anticoagulant therapy, Pregnancy, or within one week post partum, Non-compressible puncture site, Traumatic resuscitation, Refractory hypertension (systolic blood pressure >180 mm Hg), Advanced liver disease, Infective endocarditis, Active peptic ulcer

Related Conditions & MeSH terms

• Embolism
• Pulmonary Embolism

Intervention

Device:
• Ultrasound assisted Thrombolysis
Please see Arms
• Percutaneous Embolectomy
Please see arms

Drug:
• Heparin
Active comparator

Locations

Country	Name	City	State
Denmark	Copenhagen University Hospital Bispebjerg Hospital	Bispebjerg
Denmark	Copenhagen University Hospital Rigshospitalet	Copenhagen
Denmark	Copenhagen University Hospital Gentofte	Gentofte	Capital Region
Denmark	Copenhagen University Hospital, Herlev Gentofte Hospital	Herlev

Sponsors (3)

Lead Sponsor	Collaborator
Jesper Kjaergaard	Copenhagen University Hospital at Herlev, Zealand University Hospital

Country where clinical trial is conducted

Denmark, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Thrombus burdon reduction (intervention vs. heparin)	Reduction in modified Miller score (score of thrombus involvement and segmental flow) comparing percutaneous treated groups (embolectomy and USAT combined) to heparin/LMWH group, p<0.01 (n=140 vs. n=70)	To end of inclusion + 96 hours
Primary	Thrombus burdon reduction (USAT vs. embolektomy)	Reduction in modified Miller score (score of thrombus involvement and segmental flow) comparing percutaneous embolectomy and USAT, p<0.04 (n=70 vs n=70)	To end of inclusion + 96 hours
Secondary	Bleeding complications (major and minor bleeding complication according the TIMI classification)	TIMI classification	3 months
Secondary	Duration of index admission, including hospital based rehabilitation	Duration of index admission	3 months
Secondary	Dyspnea index (Visual analog scale) after 48-96 hours and after 3 months	Duration of index admission	96 hours and 3 months
Secondary	Rate of further interventions for pulmonary embolism during index admission	(embolectomy, full dose thrombolysis, mechanical ventilation, need for vasopressors, cardio pulmonary resusuctation, VA-ECMO etc)	3 months
Secondary	Mortality in the three groups (log-rank), and hazard ratio in multivariable analysis using the UFH/LMWH as reference. Inclusion date of last patient's 3 month follow-up defines last day of follow-up	Clinical outcome	1 year on avarage, at least 3 months
Secondary	Incidence of TR gradient > 40 mmHg at 3 months follow-up echocardiography	Incidence of TR suggestive of pulmonary hypertension	through study completion, an average of 1 year
Secondary	6MWD at 3 months comparing the three groups	Functional test	3 months
Secondary	Quality of life at 3 months follow-up comparing the three groups (PEmbQoL)	QoL	3 months